Response Evaluation Of Liver Metastases From Colorectal Cancer Treated With Chemotherapy By Contrast-Enhanced Ultrasonography With Quantification

Objective:To explore the value of contrast-enhanced ultrasonography (CEUS) with quantification (bolus injection of ultrasound contrast agent with time-intensity curve) in early response evaluation of liver metastases from colorectal cancer treated with cytotoxic chemotherapy, supplemented by bevacizumab or not.Methods:28patients who had liver metastases from colorectal cancer were divided into two treatment groups:mFOLFOX6supplemented by bevacizumab and not. Conventional US and CEUS were performed one day before the first, second, third and fourth chemotherapy (dayl, day15, day29, day43). Contrast Dynamic Software was made use of and percentage changes of all quantitative parameters between day15and day1were calculated. Parameters’percentage changes between responders and non-responders were compared respectively for both treatment groups to analyze correlativity with response evaluation criteria in solid tumors (RECIST).Results:Percentage changes of peak intensity (PI) between responders and non-responders in combined treatment group were statistically different (0.02<P<0.05),while other parameters were not; for mFOLFOX6treatment group, all parameters’percentage changes were not statistically different between responders and non-responders.Conclusion:CEUS quantitative analysis allows early response evaluation of liver metastases from colorectal cancer treated with mFOLFOX6supplemented by bevacizumab.This research contains2figures,4tables and21references.